Muscular Dystrophy Canada in partnership with the Neuromuscular Disease Network for Canada’s Clinical Trial Network is excited to host the second of three Hope on the Horizon events. These events are geared towards patients and family members within the neuromuscular community.

Join us to learn more about the treatment and clinical trial landscape for Myotonic Dystrophy Type 1 from key experts in the field – Drs. Charles Kassardjian, Hanns Lochmüller and Cynthia Gagnon.

The objectives of this session are as follows:

• To present current clinical practice guidelines and multidisciplinary management strategies for Myotonic Dystrophy Type 1.
• To provide accessible summaries of ongoing clinical trials, including their purpose, design, and eligibility criteria.
• To introduce promising therapies currently in development and explain their mechanisms and projected timelines.
• To equip individuals and families with tools to make informed choices about care and research participation.
• To strengthen connections between the community and the broader healthcare and research ecosystems.

If you have any questions, please email

Upcoming Hope on the Horizon events:

• Nov 28, 2025: Myasthenia Gravis